EICHORPublic-registry trials using Empagliflozin that Eichor's radar has found — 2 trials. All data below is from public sources; Eichor is not affiliated with any sponsor.
Empagliflozin appears in 2 registered trials Eichor's radar has found, across 2 sponsors, the most recent registered as Phase 2, with a planned enrollment of 1,664. Registered timeline: 2022–2025. The registry holds 5,725 registered studies for Chronic Kidney Disease.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes | Bayer | Type 2 Diabetes Mellitus | PHASE2 | 185 |
| Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | PHASE2 | 42 |
| Status | Completed · planned start 2022-06 |
| Primary completion | 2025-03 |
| Enrollment target | 1,664 participants |
| Design | Randomized · Parallel · Phase 2 · 3 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 173 listed in Belgium, Canada, Denmark, France |
All fields verbatim from the ClinicalTrials.gov record for NCT05254002.
| Status | Completed · planned start 2022-06 |
| Primary completion | 2024-03 |
| Enrollment target | 42 participants |
| Design | Randomized · Parallel · Phase 2 · 3 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 42 listed in Belgium, France, Netherlands, United Kingdom |
All fields verbatim from the ClinicalTrials.gov record for NCT05232071.
| First FDA approval | JARDIANCE — August 2014 (application NDA204629, currently held by BOEHRINGER INGELHEIM) |
| Approval timeline | JARDIANCE 2014 (BOEHRINGER INGELHEIM) → GLYXAMBI 2015 (BOEHRINGER INGELHEIM) → SYNJARDY 2015 (BOEHRINGER INGELHEIM) → SYNJARDY XR 2016 (BOEHRINGER INGELHEIM) → TRIJARDY XR 2020 (BOEHRINGER INGELHEIM) → EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE 2022 (ZYDUS PHARMS) → EMPAGLIFLOZIN 2022 (ZYDUS PHARMS) |
| Also known as | JARDIANCE · GLYXAMBI · SYNJARDY · SYNJARDY XR · TRIJARDY XR · EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE |
| Approved applications | 7 — a multi-source (generic) drug |
| Forms & routes | Tablet, Tablet, Extended Release · Oral |
| Registry-wide use | 625 registered studies all-time · 110 currently recruiting |
Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.
The public registry holds 5,725 registered studies for Chronic Kidney Disease. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Type 2 Diabetes Mellitus drugs
← Eichor home · All tracked trials · Type 2 Diabetes Mellitus studies · Weekly briefs
